Via Scoop.itStem Cell Technology

Seattle Genetics Announces Pivotal ADCETRIS™ (Brentuximab Vedotin) Hodgkin …MarketWatch (press release)ADCETRIS is being evaluated in a phase III clinical trial (the AETHERA trial) for patients at high risk of residual Hodgkin lymphoma following…

Via news.google.com